Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Retinitis Pigmentosa
Biotech
Italian biotech raises $141M series B to fund eye gene therapies
AAVantgarde Bio has raised $143 million in series B funds that the Italian biotech will use to push its two gene therapies through the clinic.
James Waldron
Nov 3, 2025 3:00am
Beacon shines a light on positive early data from eye disease ph. 2
May 7, 2025 7:15am
J&J gene therapy fails ph. 3 rare eye disease trial
May 5, 2025 11:33am
NIH creates eye drops that protect mice from vision loss
Mar 25, 2025 3:10pm
MeiraGTx gifts last of gene therapy rights to J&J for $415M
Dec 21, 2023 10:14am
ProQR, Théa ink new pact for eye assets after old one collapsed
Dec 8, 2023 11:01am
